1. Sudden Cardiac Arrest Key Facts. Heart Rhythm Foundation (http://www.hrsfoundation.org/facts/scd.asp#1).

2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6): e85-151.

3. Curtis LH, Al-Khatib SM, Shea AM, et al. Sex differences in the use of implantable cardioverterdefibrillators for primary and secondary prevention of sudden cardiac death. Jama 2007; 298(13): 1517-24.

4.Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter defibrillators among patients hospitalized with heart failure. JAMA 2007; 298(13): 1525-32.

5. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.

6. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. N Engl J Med 2005;352:225-37.

7. Cutler, M. J. and D. S. Rosenbaum. Explaining the clinical manifestations of T wave alternans in patients at risk for sudden cardiac death. Heart Rhythm 2009;6(3): S22-S28.

8. Rosenbaum DS, Jackson LE, Smith JM, et al. Electrical Alternans and Vulnerability to Ventricular Arrhythmias. N Engl J Med 1994; 330(4): 235-241.

9. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac. Circulation 2006; 114(10): e385-484.

10. CMS Decision Memorandum for Microvolt T-wave Alternans Testing. http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=165 2006.